• Burning Rock Biotech narrowed net loss 84% to RMB 55.3 million (US$ 7.9 million) for fiscal year 2025.
• Revenue climbed 4.6% to RMB 539.6 million (US$ 77.2 million).
• Gross margin rose 4.4 percentage points to 74.7%.
• Central laboratory revenue fell 8.9% to RMB 160 million, while pharma research and development services jumped 34.5% to RMB 155.5 million on increased development and testing services.
• Cash, cash equivalents and restricted cash ended year at RMB 481.1 million (US$ 68.8 million), with management expecting liquidity to cover general corporate needs for at least the next 12 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-183377), on April 28, 2026, and is solely responsible for the information contained therein.